Amyotrophic lateral sclerosis & frontotemporal degeneration · 2024
Gut metabolomic and microbiota analyses in ALS mice reveal specific metabolites despite the absence of significant gut dysbiosis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Veyrat-Durebex Charlotte, Osman Samira, Al Ojaimi Yara, Gosset Philippe, Dupuy Camille, Lefevre Antoine, Emond Patrick, Vourc'h Patrick, Corcia Philippe, Mereghetti Laurent, Kempf Florent, Raoul Cédric, Blasco Hélène
Аннотация
OBJECTIVE: Over the past years, interest in the role of gut microbiota in neurodegenerative diseases has emerged. Despite numerous publications over the past decade, both in human and pre-clinical studies, there is no clear consensus on the microbiota's role or involvement in ALS. Few studies on mouse models of ALS highlighted a correlation between specific bacteria species and the prognostic or severity of the disease. Still these results lack reproducibility and remain controverted. In this article we present a study of fecal microbiota in the SOD1G93A mouse model associated with a metabolomic analysis of cecum content, compared to controls.
METHODS: Intestinal metabolomic profile and fecal microbiota were assessed in two cohorts of SODG93A mice compared to wildtype controls at the terminal stage of the ALS disease.
RESULTS: Results showed a significant difference in metabolomic profile in SOD1G93A mice compared to controls but without a marked change in composition and diversity of fecal microbiota. Nevertheless, we observed an increase of Lachnospiraceae family, which are butyrate-producer bacteria, in SOD1G93A mice. Moreover, some metabolites with significantly different intestinal concentrations are partially produced and linked with intestinal bacteria, such as riboflavin, hippurate, and N-acetylputrescine, leaving us convinced of the interest in looking further into the role of the microbiota in ALS.
CONCLUSIONS: Despite an alteration of the intestinal metabolome in SOD1G93A mice, microbiota data did not show significant changes, underlying the need for further research.
METHODS: Intestinal metabolomic profile and fecal microbiota were assessed in two cohorts of SODG93A mice compared to wildtype controls at the terminal stage of the ALS disease.
RESULTS: Results showed a significant difference in metabolomic profile in SOD1G93A mice compared to controls but without a marked change in composition and diversity of fecal microbiota. Nevertheless, we observed an increase of Lachnospiraceae family, which are butyrate-producer bacteria, in SOD1G93A mice. Moreover, some metabolites with significantly different intestinal concentrations are partially produced and linked with intestinal bacteria, such as riboflavin, hippurate, and N-acetylputrescine, leaving us convinced of the interest in looking further into the role of the microbiota in ALS.
CONCLUSIONS: Despite an alteration of the intestinal metabolome in SOD1G93A mice, microbiota data did not show significant changes, underlying the need for further research.